Literature DB >> 23401450

Non-small-cell lung cancer: then and now.

Joan H Schiller1, David R Gandara, Glenwood D Goss, Everett E Vokes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23401450     DOI： 10.1200/JCO.2012.47.5772

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  14 in total

1.  FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.

Authors:  Dickran Kazandjian; Gideon M Blumenthal; Huan-Yu Chen; Kun He; Mona Patel; Robert Justice; Patricia Keegan; Richard Pazdur
Journal:  Oncologist       Date:  2014-08-28

2.  Patient-Centered Approach to Benefit-Risk Characterization Using Number Needed to Benefit and Number Needed to Harm: Advanced Non-Small-Cell Lung Cancer.

Authors:  Gokaraju K Raju; Sean Khozin; Karthik Gurumurthi; Reuben Domike; Janet Woodcock
Journal:  JCO Clin Cancer Inform       Date:  2020-08

3.  Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.

Authors:  Julian C Schink; Julia R Trosman; Christine B Weldon; Kalliopi P Siziopikou; Gregory J Tsongalis; Alfred W Rademaker; Jyoti D Patel; Al B Benson; Edith A Perez; William J Gradishar
Journal:  J Natl Cancer Inst       Date:  2014-09-12       Impact factor: 13.506

4.  Network analysis in the identification of special mechanisms between small cell lung cancer and non-small cell lung cancer.

Authors:  Weisan Zhang; Qiang Zhang; Mingpeng Zhang; Yun Zhang; Fengtan Li; Ping Lei
Journal:  Thorac Cancer       Date:  2014-10-23       Impact factor: 3.500

5.  The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells.

Authors:  Roberto Gomez-Casal; Chitralekha Bhattacharya; Michael W Epperly; Per H Basse; Hong Wang; Xinhui Wang; David A Proia; Joel S Greenberger; Mark A Socinski; Vera Levina
Journal:  Cancers (Basel)       Date:  2015-05-22       Impact factor: 6.639

6.  Analysis for the mechanism between the small cell lung cancer and non-small cell lung cancer combing the miRNA and mRNA expression profiles.

Authors:  Weisan Zhang; Qiang Zhang; Mingpeng Zhang; Yun Zhang; Fengtan Li; Ping Lei
Journal:  Thorac Cancer       Date:  2015-01-07       Impact factor: 3.500

7.  FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.

Authors:  Dickran Kazandjian; Daniel L Suzman; Gideon Blumenthal; Sirisha Mushti; Kun He; Meredith Libeg; Patricia Keegan; Richard Pazdur
Journal:  Oncologist       Date:  2016-03-16

8.  Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.

Authors:  Dickran Kazandjian; Gideon M Blumenthal; Lola Luo; Kun He; Ingrid Fran; Steven Lemery; Richard Pazdur
Journal:  Oncologist       Date:  2016-06-21

9.  Signaling protein signature predicts clinical outcome of non-small-cell lung cancer.

Authors:  Bao-Feng Jin; Fan Yang; Xiao-Min Ying; Lin Gong; Shuo-Feng Hu; Qing Zhao; Yi-Da Liao; Ke-Zhong Chen; Teng Li; Yan-Hong Tai; Yuan Cao; Xiao Li; Yan Huang; Xiao-Yan Zhan; Xuan-He Qin; Jin Wu; Shuai Chen; Sai-Sai Guo; Yu-Cheng Zhang; Jing Chen; Dan-Hua Shen; Kun-Kun Sun; Lu Chen; Wei-Hua Li; Ai-Ling Li; Na Wang; Qing Xia; Jun Wang; Tao Zhou
Journal:  BMC Cancer       Date:  2018-03-06       Impact factor: 4.430

10.  CONCORD biomarker prediction for novel drug introduction to different cancer types.

Authors:  Youngchul Kim; Patrick M Dillon; Taesung Park; Jae K Lee
Journal:  Oncotarget       Date:  2017-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.